XXII Stock Analysis
XX
Uncovered
22nd Century Group Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. The company is headquartered in Williamsville, New York and currently employs 198 full-time employees. The company went IPO on 2006-10-17. The firm is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. In tobacco, hemp/cannabis, and hop plants, it uses various plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new plants with optimized alkaloid and flavonoid profiles, as well as improved yields and valuable agronomic traits. The company has developed very low nicotine content (VLNC) tobacco and cigarettes, which contain 95% less nicotine than conventional tobacco and cigarettes. Its reduced nicotine cigarettes include VLN King and VLN Menthol King. In hemp, the Company is developing hemp varieties with increased levels of certain cannabinoids and other desirable agronomic traits. The firm has an interest in RX Pharmatech Ltd (RXP).